Related Experiment Videos
Assessment of a universal, school-based hepatitis B vaccination program
S Dobson1, D Scheifele, A Bell
1Vaccine Evaluation Center, British Columbia's Children's Hospital, Vancouver, Canada.
JAMA
|October 18, 1995
Summary
The hepatitis B vaccination program for grade 6 students in British Columbia was highly successful, with excellent acceptance and completion rates. The vaccine proved safe and highly effective, achieving protective antibody levels in 98% of students.
Area of Science:
- Public Health
- Immunology
- Vaccinology
Background:
- Hepatitis B poses a significant global health risk.
- Universal vaccination programs are crucial for disease control.
- School-based vaccination offers an efficient delivery model.
Purpose of the Study:
- To evaluate the hepatitis B vaccination program for grade 6 students in British Columbia.
- Assess program acceptability, completion rates, and safety.
- Determine vaccine immunogenicity and adverse event profiles.
Main Methods:
- Cohort study design in British Columbia, Canada.
- Engerix-B vaccine administered at 0, 1, and 6 months.
- Monitored acceptance, completion, adverse events, and seroresponse.
Main Results:
- High enrollment (95.4%) and series completion (95.6%) achieved.
- Minor adverse events were infrequent; severe events were rare (e.g., one anaphylaxis).
- 98% of students achieved protective antibody levels post-vaccination.
Conclusions:
- School-based hepatitis B vaccination for preadolescents is highly acceptable and efficient.
- The program demonstrated strong safety and immunogenicity.
- Supports the expansion of similar public health initiatives.